A family affair: IL-17 cytokines
as drivers of disease in psoriasis

                                      

 

Friday, 30 October 2020
13:00 - 14:00 CET

Please join us for an educational symposium discussing the evolving expectations in treating psoriasis, and how therapeutics targeting the IL-17 family cytokines may help address the complexities of the disease.

This programme does not qualify for Continuing Medical Education (CME) Credit. 

Pre-register Now

Symposium Objectives

Faculty

Prof Kristian Reich (Chair)

University Medical Center Hamburg-Eppendorf, Germany

Prof Kristian Reich, Dr med. born 1965, is Professor for Translational Research in Inflammatory Skin Diseases at the Institute for Health Services Research in Dermatology and Nursing, University Clinic Hamburg-Eppendorf. He is the founder and medical director of Skinflammation, Hamburg, a centre specialised in clinical research, patient care and medical education. Since 2013, he has also been a partner at the Dermatologikum Berlin. The main areas of clinical expertise of the dermatologist and allergologist are autoimmune diseases and allergies, atopic dermatitis, psoriasis and related disorders.

Professor Reich studied German Literature, Philosophy and Medicine in Freiburg and Munich and worked as a resident in internal medicine and clinical immunology at the Klinikum Rechts der Isar of the Technische Universität München and the Eberhard-Karls-Universität Tübingen. He participated as a research fellow in programmes on T-cell activation and new drug development in cooperation with the Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Harvard Medical School, Boston and the Cedars-Sinai Medical Center, Los Angeles. Professor Reich finished his doctoral thesis in mucosal immunology with summa cum laude 1995 in Munich and his Habilitation (PhD equivalent) in skin immunology following his final exam as consultant dermatologist in Göttingen. In 2003, he was appointed University Professor and Vice Director of the Dermatology Department at the Georg-August-Universität Göttingen.

His main research interests include genetic and immunological mechanisms of cutaneous inflammatory disorders and cancer, the development of new therapies for skin diseases and health care research in psoriasis and atopic dermatitis. He has published more than 300 articles in international peer-reviewed journals, among them The Lancet, the New England Journal of Medicine, the Journal of Immunology and the Journal of Allergy and Clinical Immunology. Professor Reich chairs the scientific committee of the German Psoriasis Registry PsoBest, is a member of the board of PsoNet e.V. and the ProDerma foundation in Hamburg and is a member of the board of trustees of the Alfred-Marchionini Foundation. He is a councillor on the International Psoriasis Council and the International Eczema Council.

Professor Reich received numerous prizes and rewards including the Herbert-Herxheimer Research Prize of the German Society for Immunology and Allergology (2003), the R.K. Schachter Lectureship (2012), and the Stars of the Academy Award of the American Academy of Dermatology (2016).

Prof Richard Warren

The University of Manchester, UK

Prof Richard Warren is Professor of Dermatology and Therapeutics and Honorary Consultant Dermatologist at The University of Manchester. He graduated from Liverpool University with a first-class honours degree in Pharmacology and gained his Medical degree, with honours, one year later. He was awarded The J Hill Abram prize–highest mark in Medicine, and the Reginald Dora Goodrick prize–highest mark in Surgery. His work in Dermatology has focussed on pharmacogenetics (forming the basis of his PhD thesis), the genetic susceptibility to psoriasis and, more recently, biological therapies and their use in the treatment of psoriasis. For his work in the pharmacogenetics of methotrexate, he has received national and international awards from the British Association of Dermatologists (BAD) and American Academy of Dermatology. He is widely published in the field of Dermatology with over 200 abstracts, papers and book contributions, including The Lancet, Nature Genetics and The Journal of Investigative Dermatology. He is currently the EU Editor in Chief for the journal Dermatology and Therapy. He has been an invited plenary speaker at major national and international dermatology meetings and is a member of The International Psoriasis Council. He currently chairs the BAD guideline group for methotrexate and is a member of the BAD biologics committee and research subcommittee. In 2012, he was the expert panel member on the National Institute for Health and Clinical Excellence guideline group for psoriasis. He is co-lead of one of the two workstreams involved in the successful funding from the Medical Research Council-stratified medicine grant (value £7 million)–Psoriasis Stratification to Optimise Relevant Therapies (PSORT). He is the Director of the Dermatopharmacology unit, one of the largest clinical trial units in Europe. He co-established a clinic for patients with severe psoriasis and psoriatic arthritis in 2010 with Dr Hector Chinoy, which has received wide acclaim and is used as a national exemplar.

Dr Sandy McBride

Royal Free London, NHS Foundation Trust, UK

Dr Sandy McBride is a Consultant Dermatologist at the Royal Free Hospital, London and co-leads the Royal Free multidisciplinary psoriasis service. This service aims not only to manage patients medically, but also to address the considerable psychological and social impact of psoriasis.

She has an interest in the psychological and social impact of skin conditions and the comprehensive management of patients with psoriasis. She has set up one of the few integrated psychology and dermatology services in the UK.

Dr McBride also researches into the wider impact of psoriasis and aims to integrate research findings into clinical practice.

We look forward to having you join us for this exciting symposium!
For more information, please review our speaker’s video invitation:

Pre-register

This Site is neither intended nor designed to record or report adverse event information or product quality complaints. As required we will need to report the information to the applicable health authority even if already reported by you directly to UCB or the health authority. We may be required to follow up with you for more information. All information shared with UCB Drug Safety will be kept confidential. For reporting adverse events or product quality complaints associated with the use of a UCB product, please use the UCB side effect reporting form at https://pci.ucb.com/ or contact your local Drug Safety Office (http://www.ucb.com/worldwide). If you are an investigator participating in a UCB-sponsored study, please report any adverse event associated with the study in the clinical trial electronic data capture system, accordingly.

*We will do our best to get your question addressed by our speakers at the event, however, if that is not possible, please liaise with your local UCB medical representative after the event. All presentations and answers to Q&As represent the opinions of the presenter and do not represent the position or the opinion of UCB.